Cargando…
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design
BACKGROUND: Carcinoma of unknown primary origin (CUP) accounts for 2%–5% of newly diagnosed advanced malignancies, with chemotherapy as the standard of care. CUPISCO (NCT03498521) is an ongoing randomized trial using comprehensive genomic profiling (CGP) to assign patients with CUP to targeted or im...
Autores principales: | Ross, Jeffrey S., Sokol, Ethan S., Moch, Holger, Mileshkin, Linda, Baciarello, Giulia, Losa, Ferran, Beringer, Andreas, Thomas, Marlene, Elvin, Julia A., Ngo, Nhu, Jin, Dexter X., Krämer, Alwin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930409/ https://www.ncbi.nlm.nih.gov/pubmed/33219618 http://dx.doi.org/10.1002/onco.13597 |
Ejemplares similares
-
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience
por: Pauli, Chantal, et al.
Publicado: (2021) -
Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary
por: Wang, Xin, et al.
Publicado: (2023) -
Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary
por: Fusco, Michael J, et al.
Publicado: (2022) -
Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
por: Danziger, Natalie, et al.
Publicado: (2023) -
Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer
por: Murugesan, Karthikeyan, et al.
Publicado: (2022)